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Variability of Growth in Children Starting Antiretroviral
Treatment in Southern Africa
WHAT’S KNOWN ON THIS SUBJECT: HIV-infected children on
antiretroviral therapy in low-income settings show initial catch-up
in weight and height growth during the ﬁrst years of treatment,
but long-term outcomes remain unknown.
WHAT THIS STUDY ADDS: We demonstrate that even after 3 years
on antiretroviral therapy, normal values were not reached.
Although catch-up growth in weight stagnated after the ﬁrst year,
catch-up growth in height was slower but continued over the
whole period.
abstract
BACKGROUND: Poor growth is an indication for antiretroviral therapy
(ART) and a criterion for treatment failure. We examined variability in
growth response to ART in 12 programs in Malawi, Zambia, Zimbabwe,
Mozambique, and South Africa.
METHODS: Treatment naïve children aged ,10 years were included.
We calculated weight for age z scores (WAZs), height for age z scores
(HAZs), and weight for height z scores (WHZs) up to 3 years after
starting ART, by using the World Health Organization standards. Mul-
tilevel regression models were used.
RESULTS: A total of 17 990 children (range, 238–8975) were followed
for 36 181 person-years. At ART initiation, most children were under-
weight (50%) and stunted (66%). Lower baseline WAZ, HAZ, and WHZ
were the most important determinants of faster catch-up growth on
ART. WAZ and WHZ increased rapidly in the ﬁrst year and stagnated or
reversed thereafter, whereas HAZ increased continuously over time.
Three years after starting ART, WAZ ranged from 22.80 (95% conﬁ-
dence interval [CI]: 23.66 to 22.02) to 21.98 (95% CI: 22.41 to 2
1.48) in children with a baseline z score , 23 and from 20.79 (95%
CI: 21.62 to 0.02) to 0.05 (95% CI: 20.42 to 0.51) in children with
a baseline WAZ $ 21. For HAZ, the corresponding range was 22.33
(95% CI: 22.62 to 22.02) to 21.27 (95% CI: 21.58 to 21.00) for
baseline HAZ , 23 and 20.24 (95% CI: 20.56 to 0.15) to 0.84 (95%
CI: 0.53 to 1.16) for HAZ $ 21.
CONCLUSIONS: Despite a sustained growth response and catch-up
growth in children with advanced HIV disease treated with ART, normal
weights and heights are not achieved over 3 years of ART. Pediatrics
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Growth retardation is common among
HIV-infected children in general and in
particular in low income settings.1–3
Reasons for growth retardation are
multifactorial and include genetic and
environmental factors such as poor
nutrition, low socioeconomic status,
and infection by different pathogens.4,5
All of these factors are interrelated and
may decrease immunity and lead to
malabsorption of food and to endocrine
dysfunction.6 Growth monitoring identi-
ﬁes HIV-infected children eligible for
antiretroviral therapy (ART) and is useful
to assess response to therapy,1,7 and it is
particularly important in many settings
in sub-Saharan Africa with limited ac-
cess to CD4 count and viral load moni-
toring to assess treatment failure.
Although most studies from sub-
Saharan Africa described positive
short-term responses of weight and
height,8–10 results were not consistent
and only few studies revealed growth
response beyond 2 years on ART11–13;
several studies revealed no improve-
ments in height9,13,14 or stagnation af-
ter a short time period,15 whereas
others revealed continuous improve-
ments.1,12,16–18 Similarly, most studies
revealed marked improvements in
weight gain after ART start,1,12,16,19 but
some studies revealed no improve-
ments.11,20 The short follow-up dura-
tion, wide age range (including many
older children starting ART as they
approach puberty), and the variability
in access to virologic monitoring could
explain some of the differences and
also be a reason that, in general, values
similar to those of HIV-uninfected chil-
dren were not reached in resource-
limited settings.
The aim of this study is to describe
growth responses up to 3 years after
ART initiation, to describe variability of
growth response between different
cohorts, and to examine associations
between patient and site characteristics
withgrowth response inSouthernAfrica.
METHODS
Study Population
The International Epidemiological Data-
bases to Evaluate AIDS, Southern Africa
(IeDEA-SA) collaboration includes 24
programs in 6 southern African coun-
tries (www.iedea-sa.org). Data are col-
lected at each site as part of routine
monitoring at baseline (ART initiation)
and each follow-up visit, by using stan-
dardized deﬁnitions. Data from the dif-
ferent sites are transferred to data
centers at the Universities of Cape
Town, South Africa, or Bern, Switzer-
land, in a standardized format and
merged at regular intervals. All IeDEA-
SA sites with at least 100 children on
ART were included.
ART-naïve children who initiated
treatment with at least 3 antiretroviral
drugs at age ,10 years were in-
cluded. We excluded children who
were transferred from another site. A
child was considered lost to follow-
up if the time between the last visit
and the closing date of the cohort
was longer than 6 months. Weight
and height measurements were con-
verted into age- and gender-adjusted z
scores by using the latest World
Health Organization (WHO) growth
standards from 2007.21 Underweight
was deﬁned as weight for age z score
(WAZ) , 22, stunting as height for
age z score (HAZ) , 22, and wasting
as weight for height z score (WHZ) ,
22. For WHZ, the analysis was limited
to children aged 2 to 5 years because
WHO reference values were only
available for this age group. We took
weight and height measurements and
CD4 cell counts closest to the starting
date of ART (26 months/+1 week) as
baseline values.
Statistical Analysis
We used a multilevel model to account
for the hierarchical structure of
the data (ie, repeated anthropomet-
ric measurements within a child
and children belonging to differ-
ent cohorts). To model the nonlinear
increase of the anthropometric mea-
surements on ART over time most
accurately, we used a second order
fractionalpolynomial transformationof
time22 as described previously.1 All
available weight and height measure-
ments from ART initiation up to 3 years
afterward were included in the analy-
sis, provided the child had a baseline
and at least 1 weight or height mea-
surement after the start of ART. The
adjusted model included the following
variables at ART initiation: gender; age
(,2, 2–4, and 5–10 years); WAZ, HAZ,
and WHZ (,23, $23 to ,22, $22
to,21, and$21); WHO clinical stage
(1 or 2, 3, and 4); degree of immu-
nodeﬁciency (“severe,” “advanced,”
“mild,” and “asymptomatic” according
to WHO criteria23); type of ART regimen
(nonnucleoside reverse transcriptase
inhibitor [NNRTI]-based, protease in-
hibitor [PI]-based, other, and un-
known); and time period of ART start
(1997–2005, 2005–2006, 2006–2007,
and 2008–2010). We also included
interactions between time and all
baseline variables because it can be
expected that growth response varies
by baseline variables. The model was
ﬁtted by using a fully probabilistic ap-
proach (see Appendix). The model ﬁt
was visually assessed by plotting the
predicted median with 95% prediction
intervals and the observed trajectories
for individual children and by the de-
viance information criterion. Missing
values of stage of disease, degree of
immunodeﬁciency, and type of regimen
were imputed. We used multinomial
regression models with stage of dis-
ease, degree of immunodeﬁciency, and
type of regimen as outcome and age,
gender, year of starting ART, and
baseline z score at start of ART as
predictors. Missing data were imputed
by randomly sampling from the pre-
dictive multinomial distribution. Crude
and adjusted estimates of z scores
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were shown over time and by treat-
ment site. In addition, we created 1000
z-score trajectories based on the ad-
justed model and calculated the per-
centages of children in each z-score
category over time. We performed 2
additional analyses: a complete case
analysis without multiple imputation
and an analysis where we included
only children who were followed for at
least 3 years. A particular risk factor
was deﬁned as being associated with
faster catch-up growth if it was asso-
ciated with higher z scores at 1 year
after initiating ART. All analyses were
done in R-2.11.1 (The R Development
Core Team, University of Vienna, Vienna,
Austria), Stata version 11 (Stata Corp,
College Station, TX), and WinBUGS 1.4.3
(Lunn et al 2010). In all sites, in-
stitutional review boards approved the
participation in IeDEA-SA.
RESULTS
Study Population and Baseline
Characteristics
A total of 17 990 children from 12 pro-
grams in Malawi, Zambia, Zimbabwe,
Mozambique, and South Africa were
included and followed for 36 181
person-years from date of ART initia-
tion. Table 1 shows the characteristics
of the sites and gives more details on
anthropometric measurements and
food supplementation. In the ﬁrst 3
years after ART start, 1183 children
died (rate 3.3 per 100 person-years),
2611 were lost to follow-up (7.2 per 100
person-years), and 878 were trans-
ferred out of care in the particular
sites (2.4 per 100 person-years).
Table 2 shows the characteristics of the
children at ART initiation by treatment
site. One-third of children were aged
#2 years, and 37.8% were 5 years or
older. Most children were underweight
(49.7%) and stunted (66.1%). The me-
dian number of measurements after
start of ARTwas 6 (interquartile range
[IQR]: 2–13) for weight and 4 (IQR:
1–10) for height. The 17 990 children
included in the analysis contributed 154
775 weight measurements and 123 006
height measurements. A total of 11 015
children had a baseline height available
and were thus included in the analysis
for HAZ, and 4155 children were aged
2 to 5 years and had a baseline weight
and height available and were thus in-
cluded in the analysis for WHZ.
Weight for Age
Three years after starting ART, WAZ
across sites ranged from 22.80 (95%
conﬁdence interval [CI]: 23.66 to 2
2.02) to21.98 (95% CI:22.41 to21.48)
in children who started with a baseline
z score of,23 and from20.79 (95%
CI:21.62 to 0.02) to 0.05 (95% CI:20.42
to 0.51) in children with a baseline WAZ
$ 21 (Supplemental Fig 5). Catch-up
growth was fastest in the ﬁrst year and
was particularly pronounced in the 2
tertiary sites (numbers 6 and 7). No
difference was apparent between sites
that do or do not measure viral load
routinely. Figure 1 shows the results
from the adjusted analyses. Estimated
z scores per cohort are shown for
a “typical child” (ie, a girl aged 5 years
or older, who started ART after 2007
with an NNRTI-based regimen, was in
WHO stage 3, and was severely immu-
nodeﬁcient). Adjustment for baseline
differences reduced the heterogeneity
of WAZ across sites, and in particular
growth response in the tertiary sites
became more similar to other sites.
Lower baseline z scores, younger age,
advanced stage of the disease, more
advanced immunodeﬁciency, and a PI-
based regimenwere predictive of faster
catch-up growth in WAZ, and there was
a 3-way interaction between type of
regimen, baseline z score, and age (P,
.001). This means that the effect of the
type of regimenwas not only different in
each baseline z-score category but also
in each age group within each z-score
category. No effect was seen for the year
of ART start and gender.
Height for Age
Figure 2 and Supplemental Fig 6 show
adjusted and crude analyses for height
for age. Three years after starting ART,
HAZ across sites ranged from 22.33
(95% CI:22.62 to22.02) to21.27 (95%
CI: 21.58 to 21.00) in children who
startedwith a baseline z score of,23
and from20.24 (95% CI:20.56 to 0.15)
to 0.84 (95% CI: 0.53 to 1.16) in children
with a baseline HAZ$ 21. As for WAZ,
pooled estimates remained below zero
for all but the highest baseline z-score
group. For growth in height, the pattern
is, however, different in several ways;
catch-up growth is slower in the ﬁrst
year of ART, but it is continuous during
the whole 3-year time period for all
children who start ART with HAZ base-
line values , 21. Heterogeneity be-
tween sites was smaller than for WAZ,
and again no difference between viral
load sites and nonviral load sites was
apparent. For HAZ, the predictors for
growth response were similar as for
WAZ with the exception of age where
the youngest children showed the
slowest growth response, and stage of
disease and degree of immunodeﬁ-
ciency were not associated with height
growth response.
Weight for Height
Supplemental Figs 7 and 8 show crude
and adjusted analyses for WHZ. Three
years after starting ART, WHZ ranged
from24.03 (95% CI:25.44 to22.60) to
22.36 (95% CI: 23.52 to 21.13) in
children who started with a baseline
z score of,23 and from20.66 (95%
CI:21.43 to 0.12) to 1.01 (95% CI: 0.42 to
1.60) in children with a baseline WHZ$
21. Catch-up growth in WHZ was fast in
the ﬁrst year of ART so that normal
values were reached already within 1
year irrespective of the starting value.
As weight gain stagnated after the ﬁrst
year on ART while HAZ continued to in-
crease, WHZ decreased again after the
ﬁrst year. As for WAZ, heterogeneity
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across sites was substantial, and
adjusting for differences in baseline
variables reduced the heterogeneity
only slightly. Lower baseline z scores,
male gender, and severe immunodeﬁ-
ciency were predictive for faster catch-
up growth in WHZ. No clear effect was
seen for the year of ART start and type
of regimen.
Figure 3 shows the overall pooled
estimates across the sites for WAZ, HAZ,
and WHZ. The results from the com-
plete case and for the multiple impu-
tation were similar, whereas children
who were followed during the whole
time period had a slightly better
growth response (Supplemental Table
3). For children who were followed for
3 years, the proportion of children in
different z-score categories over time
is shown in Fig 4. Although over 60%
reached WAZ . 21, 46% reached HAZ
. 21. For WHZ, this proportion in-
creased rapidly to 90% within 1 year
but decreased again later to over 50%.
DISCUSSION
This collaborative analysis of ~18 000
children in 12 ART programs revealed
that although WAZ and WHZ improved
during the ﬁrst years of ART, there was
a reversed trend from year 2 onwards.
Although catch-up growth in weight
was faster initially, catch-up growth in
height was more constant and contin-
ued over the whole 3-year time period.
Only children with baseline WAZ and
HAZ . 21 approached normal values
within 3 years irrespective of age. In
multivariable analyses, lower baseline
WAZ, HAZ, and WHZ were the most im-
portant determinants of faster catch-
up growth on ART. The use of a PI-based
regimen was associated with faster
catch-up growth in weight and height,
whereas other variables were associ-
ated only with growth in WAZ (younger
age, advanced stage of the disease) or
in height (old age) or not at all (gender,
year of ART start).
Few studies have directly compared
weightandheightgrowthbycalculating
WHZ24 or BMI2,25–27 and data are there-
fore limited. Because children were
underweight and stunted and catch-up
growth in the ﬁrst year of ART was
particularly fast for WAZ, the degree of
wasting was only moderate and nor-
malized rapidly within 1 year. Although
the consistent increase in HAZ over 3
years is reassuring, the reasons for the
increase in the proportion of children
who are underweight or wasted after 2
years on ART need to be studied further.
Our ﬁndings differ substantially from
growth patterns in high-income set-
tings; in our study, normal values ofWAZ
and HAZ were not reached despite ob-
servinggrowthoveranextendedperiod
of time. In contrast, in a study of ART-
naïve children in the United States,
normal WAZ and HAZwere reached after
1 and 2 years of ART, respectively,2 but
baseline z scores were much higher. A
study comparing children from Uganda
and the United Kingdom and Ireland15
revealed that the median change in HAZ
after 12 months on ART was smaller in
Uganda with differences being attrib-
uted to lower baseline levels in Ugandan
children. In a European study including
nonnaïve children,25 it took 5 years to
reach normal WAZ, and HAZ did not
reach normal values.
We found that the baseline z scores
were the most important predictors of
growth response. However, although
the more severely underweight chil-
dren showed a more rapid catch-up
growth on ART, they did not reach the
same weight as children who started
with higher values. The association
between age and growth response was
smaller and less consistent across
studies; we and others found that
young age is associated with a more
rapid catch-up growth in weight but
not height,24 whereas other studies
revealed associations with weight and
height.2,28,29 It has been speculated thatTA
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younger children experience less in-
testinal damage and are therefore
better able to absorb micronutrients,
and that the shorter duration with
chronic immune activation is associ-
ated with lower metabolic costs.30,31
Alternatively, younger children may
have faster normal growth and differ-
ent growth regulation.32
The ﬁnding that growth response was
better for children on PI-based regi-
mens is topical in the light of the re-
cently presented P1060 clinical trial.33
This trial comparing lopinavir/ritona-
vir (LPV/r) versus nevirapine as ﬁrst-
line regimen for non-nevirapine exposed
infants and young children revealed
better virological and combined viro-
logical/mortality outcomes in children
on LPV/r. There was, however, a trend
toward worse growth in the LPV/r
group. Although our results indicate
that growth response may be superior
with a PI-based regimen including
LPV/r, this association was modiﬁed by
both age and baseline WAZ. There may
be unmeasured confounders, which fa-
vor the use of 1 versus the other regi-
men, and prevention of mother to
child transmission exposure is poorly
documented in the current IeDEA-SA
database.
Despite the large variability of sites,
these sites may not necessarily reﬂect
the situationof the regionasawhole; all
except 2 sites were located in urban
areas and cohorts from South Africa
predominated. However, this is one of
the largest pooled analyses of children
on ART ever published and from one of
the regionsmost heavily affected by the
HIV epidemic. Results should therefore
be applicable tomany other children on
ART. A strength of our study is the rel-
ative largenumberof youngchildren.By
limiting the analysis to children aged
,10 years, we excluded the growth
spurt during adolescence.
Although we were able to present
results up to 3 years on ART, themedian
follow-up time was shorter. Due to the
rapid scale up of ART, the majority of
children started ART only recently and
mortality and loss to follow-up were
substantial. The growth response in
these children may well differ from the
response in children who remained in
FIGURE 1
WAZs by baseline z score at ART start and 1, 2, and 3 years afterward in 12 treatment programs of IeDEA-SA (adjusted analysis). Medians and IQRs are shown
together with an overall pooled estimate. Missing values at start of ART were imputed by multiple imputation.
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care. Many studies have revealed that
mortality is high among patients lost to
follow-up,34,35 and they may have stop-
ped taking ART. If sicker patients are
more likely to get lost, our analysis
overestimates growth response. When
we repeated the analysis with children
remaining in care during the whole
time period, z scores were in general
similar or slightly higher. Therefore,
loss to follow-up may not have dis-
torted results to an important degree.
Many factors that could inﬂuence
growth response were not recorded,
whichmayexplainwhyadjusting for the
recorded baseline variables reduced
heterogeneity only moderately; we had
no individual level data on nutrition and
food supplementation, nor on socio-
economic status, tuberculosis treat-
ment, hemoglobin, birth weight, or
adherence to therapy. The presence or
absence of peripheral edema was not
recorded and therefore a nutritional
assessment based on WHO deﬁnitions
was not possible. The provision of
food supplementation that may have
affected growth trajectories and mea-
surements for shoes and clothes were
only standardized within but not be-
tween sites. Children with lower z
scores may have received food sup-
plements and may therefore have had
a better growth response. Because
we did an intention-to-treat analysis,
we ignored treatment interruptions.
Further, stage of disease does not fully
capture the severity of different coin-
fections. Similarly, the proportion of
missing data was relatively high.
Results were, however, similar
if missing values were completed by
multiple imputation and in the com-
plete case analysis. Other limitations
are that no standardized measure-
ments of weight and heights were
done, and ﬁnally that no comparisons
to HIV-negative children were possible
for the different sites.
CONCLUSIONS
This study demonstrated that although
weight and height increased rapidly on
FIGURE 2
HAZs by baseline z score at ART start and 1, 2, and 3 years afterward in 11 treatment programs of IeDEA-SA (adjusted analysis). Medians and IQRs are shown
together with an overall pooled estimate. Missing values at start of ART were imputed by multiple imputation. Cohort 12 is missing because no data about
heights are collected.
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ART and was particularly pronounced
forweight in theﬁrst yearofART,neither
weight nor height values normalized
during 3 years of ART. There is an urgent
need to better understand the reasons
for the large variability in growth re-
sponse across sites and to better
document individual level and site level
characteristics that inﬂuence response
to therapy.
APPENDIX: FULL PROBABILITY
MODEL
Let Yjk (t) denote the anthropometric
measure be it WAZ, HAZ, or WHZ for
child j = 1,...,N at time t = 1,..., Twith time
in years in cohort k = 1,..., K. The model
can be written as
The error term ε represents the mea-
surement error for each child, and in
the ﬁnal model is a centered Student’s
FIGURE 3
WAZs, HAZs, and WHZs by baseline z score at ART start and 1, 2, and 3 years afterward. Pooled adjusted estimates of treatment programs of IeDEA Southern
Africa. Medians and IQRs are shown.
Yijk ¼ ajk   þ   bjk ×ti   þ   gjk ×ti ×logðtiÞ  þ   εijk ; εijk   e  N0;s2
ajk ¼ Xaak þ hjk ;   hjkeN0; t2a
bjk ¼ Xbbk þ zjk ;   zjkeN

0; t2b

gjk ¼ Xggk þ jjk ;   jjkeN

0; t2g

ak ¼ Zaa0 þ hk ;   hkeN0; n2a
bk ¼ Zbb0 þ zk ;   zkeN

0; n2b

gk ¼ Zgg0 þ jk ;   jkeN

0; n2g

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FIGURE 4
Percentage of children in different z-score categories over time.
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t test distribution with 3 degrees of
freedom and scale parameter s2. The
children level random effects dis-
tributions are centered Student’s t
test distributions as well with 3
degrees of freedom and scale parame-
ters ta
2, tb
2, and tg
2. The cohort level
random effects distributions are cen-
tered Student’s t test distributions with
3 degrees of freedom and scale
parameters ya
2, yb
2, and yg
2. Student’s
t test distributions were preferred
because these heavy tailed dis-
tributions yield robust estimates and
outperform the model with normal
distribution in terms of the deviance
information criterion.
The prior distributions for a0, b0, and
g0 are centered normal with SD = 5. For
the other a, b, and g parameters, the
priors are centered normalwith SD= 10.
The prior distributions for all scale
parameters are inverseg distributions
with shape and rate parameters equal
to 1 and 0.01, respectively.
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